156 related articles for article (PubMed ID: 37313811)
1. [RITA selectively inhibits proliferation of
Shi W; Liu X; Zhang G; Ye L; Zhou R; Li Y; Yu L
Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):710-717. PubMed ID: 37313811
[TBL] [Abstract][Full Text] [Related]
2. BAP1 loss augments sensitivity to BET inhibitors in cancer cells.
Xu YY; Ren ZL; Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Luo X; Liu SW; Li YL; Yu L
Acta Pharmacol Sin; 2022 Jul; 43(7):1803-1815. PubMed ID: 34737422
[TBL] [Abstract][Full Text] [Related]
3. Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Kuznetsoff JN; Owens DA; Lopez A; Rodriguez DA; Chee NT; Kurtenbach S; Bilbao D; Roberts ER; Volmar CH; Wahlestedt C; Brothers SP; Harbour JW
Mol Cancer Res; 2021 Feb; 19(2):215-222. PubMed ID: 33077485
[TBL] [Abstract][Full Text] [Related]
4. BAP1 has a survival role in cutaneous melanoma.
Kumar R; Taylor M; Miao B; Ji Z; Njauw JC; Jönsson G; Frederick DT; Tsao H
J Invest Dermatol; 2015 Apr; 135(4):1089-1097. PubMed ID: 25521456
[TBL] [Abstract][Full Text] [Related]
5. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
6. BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma.
Luo X; Xu Y; Li Y; Zhang G; Huang S; Liu X; Ren Z; Liu S; Yu L
Melanoma Res; 2021 Apr; 31(2):119-129. PubMed ID: 33347048
[TBL] [Abstract][Full Text] [Related]
7. Tumours associated with BAP1 mutations.
Murali R; Wiesner T; Scolyer RA
Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
9. Biological Mechanisms and Clinical Significance of
Carbone M; Harbour JW; Brugarolas J; Bononi A; Pagano I; Dey A; Krausz T; Pass HI; Yang H; Gaudino G
Cancer Discov; 2020 Aug; 10(8):1103-1120. PubMed ID: 32690542
[TBL] [Abstract][Full Text] [Related]
10. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.
Njauw CN; Kim I; Piris A; Gabree M; Taylor M; Lane AM; DeAngelis MM; Gragoudas E; Duncan LM; Tsao H
PLoS One; 2012; 7(4):e35295. PubMed ID: 22545102
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma.
Webster JD; Pham TH; Wu X; Hughes NW; Li Z; Totpal K; Lee HJ; Calses PC; Chaurushiya MS; Stawiski EW; Modrusan Z; Chang MT; Tran C; Lee WP; Chalasani S; Hung J; Sharma N; Chan S; Hotzel K; Talevich E; Shain A; Xu M; Lill J; Dixit VM; Bastian BC; Dey A
Pigment Cell Melanoma Res; 2019 Mar; 32(2):269-279. PubMed ID: 30156010
[TBL] [Abstract][Full Text] [Related]
12. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
13. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors.
Garfield EM; Walton KE; Quan VL; VandenBoom T; Zhang B; Kong BY; Isales MC; Panah E; Kim G; Gerami P
J Am Acad Dermatol; 2018 Sep; 79(3):525-534. PubMed ID: 29753057
[TBL] [Abstract][Full Text] [Related]
14. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.
Gerami P; Yélamos O; Lee CY; Obregon R; Yazdan P; Sholl LM; Guitart GE; Njauw CN; Tsao H
JAMA Dermatol; 2015 Nov; 151(11):1235-9. PubMed ID: 26154183
[TBL] [Abstract][Full Text] [Related]
15. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
Wadt K; Choi J; Chung JY; Kiilgaard J; Heegaard S; Drzewiecki KT; Trent JM; Hewitt SM; Hayward NK; Gerdes AM; Brown KM
Pigment Cell Melanoma Res; 2012 Nov; 25(6):815-8. PubMed ID: 22889334
[TBL] [Abstract][Full Text] [Related]
16. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.
Carbone M; Ferris LK; Baumann F; Napolitano A; Lum CA; Flores EG; Gaudino G; Powers A; Bryant-Greenwood P; Krausz T; Hyjek E; Tate R; Friedberg J; Weigel T; Pass HI; Yang H
J Transl Med; 2012 Aug; 10():179. PubMed ID: 22935333
[TBL] [Abstract][Full Text] [Related]
17. Gene of the month: BAP1.
Wang A; Papneja A; Hyrcza M; Al-Habeeb A; Ghazarian D
J Clin Pathol; 2016 Sep; 69(9):750-3. PubMed ID: 27235536
[TBL] [Abstract][Full Text] [Related]
18. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
19. BAP1-Inactivated Melanoma Arising From BAP1-Inactivated Melanocytic Tumor in a Patient With BAP1 Germline Mutation: A Case Report and Review of the Literature.
Donati M; Šteiner P; Kazakov DV
Am J Dermatopathol; 2023 Feb; 45(2):117-122. PubMed ID: 36669076
[TBL] [Abstract][Full Text] [Related]
20. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]